MA26621A1 - Composition pour aerosols pharmaceutiques - Google Patents

Composition pour aerosols pharmaceutiques

Info

Publication number
MA26621A1
MA26621A1 MA25536A MA25536A MA26621A1 MA 26621 A1 MA26621 A1 MA 26621A1 MA 25536 A MA25536 A MA 25536A MA 25536 A MA25536 A MA 25536A MA 26621 A1 MA26621 A1 MA 26621A1
Authority
MA
Morocco
Prior art keywords
composition
pharmaceutical aerosols
aerosols
pharmaceutical
Prior art date
Application number
MA25536A
Other languages
English (en)
Inventor
Llorca Nathalie
Louis Olivier
Cavaillon Pascal
Rosier Patrick
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9808152.4A external-priority patent/GB9808152D0/en
Priority claimed from GBGB9814709.3A external-priority patent/GB9814709D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA26621A1 publication Critical patent/MA26621A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA25536A 1998-04-18 1999-04-15 Composition pour aerosols pharmaceutiques MA26621A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9808152.4A GB9808152D0 (en) 1998-04-18 1998-04-18 Pharmaceutical aerosol formulation
GBGB9814709.3A GB9814709D0 (en) 1998-07-08 1998-07-08 Pharmaceutical aerosol formulation

Publications (1)

Publication Number Publication Date
MA26621A1 true MA26621A1 (fr) 2004-12-20

Family

ID=26313483

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25536A MA26621A1 (fr) 1998-04-18 1999-04-15 Composition pour aerosols pharmaceutiques

Country Status (30)

Country Link
US (1) US7521042B2 (fr)
EP (1) EP1073417B1 (fr)
JP (1) JP2002512183A (fr)
KR (1) KR20010042816A (fr)
CN (1) CN1145478C (fr)
AP (1) AP2000001961A0 (fr)
AR (1) AR018183A1 (fr)
AT (1) ATE228823T1 (fr)
AU (1) AU755066B2 (fr)
BR (1) BR9909736A (fr)
CA (1) CA2328882A1 (fr)
CO (1) CO5021210A1 (fr)
DE (1) DE69904312T2 (fr)
DK (1) DK1073417T3 (fr)
EA (1) EA200000956A1 (fr)
EE (1) EE200000608A (fr)
ES (1) ES2189410T3 (fr)
HR (1) HRP20000689A2 (fr)
HU (1) HUP0101608A2 (fr)
ID (1) ID27887A (fr)
IL (1) IL139087A0 (fr)
IS (1) IS5665A (fr)
MA (1) MA26621A1 (fr)
NO (1) NO20005218L (fr)
NZ (1) NZ507619A (fr)
PE (1) PE20000433A1 (fr)
PL (1) PL343491A1 (fr)
PT (1) PT1073417E (fr)
TR (1) TR200100144T2 (fr)
WO (1) WO1999053901A1 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
US6390291B1 (en) * 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6119853A (en) * 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
ATE233084T1 (de) * 1999-04-14 2003-03-15 Glaxo Group Ltd Pharmazeutische aerosolformulierung
WO2002043702A2 (fr) † 2000-11-30 2002-06-06 Vectura Limited Compositions pharmaceutiques pour inhalation
ATE517607T1 (de) 2000-11-30 2011-08-15 Vectura Ltd Verfahren zur herstellung von partikeln zur verwendung in einer pharmazeutischen zusammensetzung
EP1581639A4 (fr) * 2002-12-17 2006-03-08 Medimmune Vaccines Inc Pulv risation haute pression de mat riaux bioactifs
ITMI20022674A1 (it) 2002-12-18 2004-06-19 Chiesi Farma Spa Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
US20050244503A1 (en) * 2003-05-19 2005-11-03 Rabinow Barrett E Small-particle pharmaceutical formulations of antiseizure and antidementia agents and immunosuppressive agents
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US7569586B2 (en) 2004-08-16 2009-08-04 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
CN104177448A (zh) * 2005-02-10 2014-12-03 葛兰素集团有限公司 使用预分选技术制备乳糖的方法以及由此形成的药物制剂
EP2054042B8 (fr) 2006-06-30 2020-06-10 iCeutica Pty Ltd Procédés de préparation de composés biologiquement actifs sous forme de nanoparticules
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
WO2010024898A2 (fr) 2008-08-29 2010-03-04 Lutonix, Inc. Procédés et appareils pour poser un revêtement sur des cathéters à ballonnet
WO2010091198A1 (fr) 2009-02-06 2010-08-12 University Of Southern California Compositions thérapeutiques comprenant des monoterpènes
PT3578169T (pt) 2009-02-26 2024-07-29 Glaxo Group Ltd Formulações farmacêuticas compreendendo 4-{(1r)-2-[(2,6- diclorobenzil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2- (hidroximetil)fenol
PT2453894E (pt) 2009-07-15 2016-02-02 Theravance Biopharma R&D Ip Llc Forma de base livre cristalina de um composto bifenilo
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
BR112012022209A2 (pt) 2010-03-03 2017-06-06 Neonc Tech Inc composições farmacêuticas compreendendo monoterpenos
HUE035763T2 (en) 2010-06-08 2018-05-28 Kobe Gakuin Educational Found Method of producing coated particles and coated particles
EP2883543B1 (fr) 2010-08-27 2016-11-16 Neonc Technologies Inc. Compositions pharmaceutiques comprenant des carbamates d'alcool périllylique
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
DK2651864T3 (en) 2010-12-17 2016-09-05 Neonc Tech Inc Methods and devices for use of isoperillylalkohol
CN102366405A (zh) * 2011-10-21 2012-03-07 江阴长风医药科技有限公司 以氢氟烷烃为抛射剂的氟替卡松丙酸酯气雾剂制剂
NZ722952A (en) * 2012-02-28 2018-12-21 Iceutica Holdings Inc Inhalable pharmaceutical compositions
SI2968313T1 (en) 2013-03-15 2018-05-31 Verona Pharma Plc Combination of medicines
EP3142701B1 (fr) 2014-05-12 2018-06-27 Verona Pharma PLC Nouveau traitement
US9522918B2 (en) 2015-02-12 2016-12-20 Neonc Technologies, Inc. Pharmaceutical compositions comprising perillyl alcohol derivatives
CN106546751A (zh) * 2016-11-16 2017-03-29 广州华弘生物科技有限公司 用于检测oct4蛋白的酶联免疫试剂盒
CN110267538B (zh) 2016-11-30 2022-04-19 尼昂克技术公司 紫苏醇-3-溴丙酮酸缀合物和治疗癌症的方法
WO2019157195A1 (fr) 2018-02-08 2019-08-15 Neonc Technologies, Inc Procédés de perméabilisation de la barrière hémato-encéphalique

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141674A (en) * 1984-03-08 1992-08-25 Phares Pharmaceutical Research N.V. Methods of preparing pro-liposome dispersions and aerosols
JP2765700B2 (ja) * 1986-08-11 1998-06-18 イノベータ・バイオメド・リミテツド マイクロカプセルを含有する医薬調合物
GB9024365D0 (en) * 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
EP0655237A1 (fr) * 1993-11-27 1995-05-31 Hoechst Aktiengesellschaft Composition d'aerosol medicinal
GB9426252D0 (en) * 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
DE69625813T2 (de) * 1995-06-12 2003-09-04 Ono Pharmaceutical Co. Ltd., Osaka Pranlukast enthaltende granula, verfahren zur herstellung der granula und verfahren zur verminderung des zusammenbackens von pranlukast
GB9606677D0 (en) * 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
AU6014098A (en) * 1996-12-31 1998-07-31 Inhale Therapeutic Systems Aerosolized hydrophobic drug

Also Published As

Publication number Publication date
EA200000956A1 (ru) 2001-04-23
PT1073417E (pt) 2003-04-30
JP2002512183A (ja) 2002-04-23
CN1145478C (zh) 2004-04-14
EE200000608A (et) 2001-08-15
AU755066B2 (en) 2002-12-05
ES2189410T3 (es) 2003-07-01
KR20010042816A (ko) 2001-05-25
WO1999053901A1 (fr) 1999-10-28
EP1073417A1 (fr) 2001-02-07
US20030157032A1 (en) 2003-08-21
CN1305369A (zh) 2001-07-25
CO5021210A1 (es) 2001-03-27
PE20000433A1 (es) 2000-05-26
AP2000001961A0 (en) 2000-12-31
IL139087A0 (en) 2001-11-25
EP1073417B1 (fr) 2002-12-04
CA2328882A1 (fr) 1999-10-28
AR018183A1 (es) 2001-10-31
BR9909736A (pt) 2000-12-19
DE69904312T2 (de) 2003-10-16
ATE228823T1 (de) 2002-12-15
IS5665A (is) 2000-10-13
PL343491A1 (en) 2001-08-27
NZ507619A (en) 2003-05-30
TR200100144T2 (tr) 2001-06-21
NO20005218D0 (no) 2000-10-17
DK1073417T3 (da) 2003-03-24
HUP0101608A2 (hu) 2002-03-28
ID27887A (id) 2001-05-03
AU3523199A (en) 1999-11-08
DE69904312D1 (de) 2003-01-16
HRP20000689A2 (en) 2001-02-28
US7521042B2 (en) 2009-04-21
NO20005218L (no) 2000-11-10

Similar Documents

Publication Publication Date Title
MA26621A1 (fr) Composition pour aerosols pharmaceutiques
ID22891A (id) Komposisi farmasi untuk kombinasi piperidinoalkanol-dekongestan
ID27415A (id) Komposisi farmaseutik
FR2775596B1 (fr) Nouvelles compositions pharmaceutiques
FI973518A (fi) Farmaseuttinen koostumus piperidinoalkanoliyhdisteille
DK1052974T3 (da) Farmaceutisk sammensætning indeholdende epothilon
IS5046A (is) Lyfjasamsetningar
NO20015175L (no) Farmasöytisk sammensetning
NO20005913L (no) Legemiddelsammensetning
PT1066027E (pt) Composicao farmaceutica de topiramato
DK0920302T4 (da) Farmaceutisk aerosolsammensætning
ID29262A (id) Komposisi farmasi
ID27201A (id) Komposisi farmasi
ID29294A (id) Komposisi farmasi
BR9507768A (pt) Composição farmacêutica
PT1227817E (pt) Composicao farmaceutica aquosa contendo ciclesonida
ID25857A (id) Komposisi farmasi
FI4488U1 (fi) Farmaseuttinen koostumus
ID18698A (id) Komposisi farmasi
FR2779145B1 (fr) Nouvelles compositions pharmaceutiques
EE200100281A (et) Analgeetiline ravimkoostis
ID26215A (id) Komposisi farmasi
ID23531A (id) Komposisi farmasi
UA2861S (uk) Форма для виливання супозиторіїв
BR1100755A (pt) composição farmacêutica